433 related articles for article (PubMed ID: 28923622)
1. Enzyme-Linked Immunospot Assay as a Complementary Method to Assess and Monitor Cytomegalovirus Infection in Kidney Transplant Recipients on Pre-emptive Antiviral Therapy: A Single-Center Experience.
Favi E; Santangelo R; Iesari S; Morandi M; Marcovecchio GE; Trecarichi EM; Salerno MP; Ferraresso M; Citterio F; Romagnoli J
Transplant Proc; 2017 Oct; 49(8):1766-1772. PubMed ID: 28923622
[TBL] [Abstract][Full Text] [Related]
2. Pre-transplant assessment of CMV-specific immune response by Elispot assay in kidney transplant recipients.
Rittà M; Costa C; Sidoti F; Ballocco C; Ranghino A; Messina M; Biancone L; Cavallo R
New Microbiol; 2015 Jul; 38(3):329-35. PubMed ID: 26147141
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of CMV-specific cellular immune response by EliSPOT assay in kidney transplant patients.
Costa C; Balloco C; Sidoti F; Mantovani S; Rittà M; Piceghello A; Fop F; Messina M; Cavallo R
J Clin Virol; 2014 Dec; 61(4):523-8. PubMed ID: 25453571
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
[TBL] [Abstract][Full Text] [Related]
5. The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients.
El Haddad L; Ariza-Heredia E; Shah DP; Jiang Y; Blanchard T; Ghantoji SS; El Chaer F; El-Haddad D; Prayag A; Nesher L; Rezvani K; Shpall E; Chemaly RF
J Infect Dis; 2019 Feb; 219(6):898-907. PubMed ID: 30295846
[TBL] [Abstract][Full Text] [Related]
6. Clinical validation of a novel enzyme-linked immunosorbent spot assay-based in vitro diagnostic assay to monitor cytomegalovirus-specific cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study.
Banas B; Steubl D; Renders L; Chittka D; Banas MC; Wekerle T; Koch M; Witzke O; Mühlfeld A; Sommerer C; Habicht A; Hugo C; Hünig T; Lindemann M; Schmidt T; Rascle A; Barabas S; Deml L; Wagner R; Krämer BK; Krüger B
Transpl Int; 2018 Apr; 31(4):436-450. PubMed ID: 29284181
[TBL] [Abstract][Full Text] [Related]
7. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
[TBL] [Abstract][Full Text] [Related]
8. Monitoring cytomegalovirus T-cell immunity in small bowel/multivisceral transplant recipients.
Chiereghin A; Gabrielli L; Zanfi C; Petrisli E; Lauro A; Piccirilli G; Baccolini F; Dazzi A; Cescon M; Morelli MC; Pinna AD; Landini MP; Lazzarotto T
Transplant Proc; 2010; 42(1):69-73. PubMed ID: 20172283
[TBL] [Abstract][Full Text] [Related]
9. Evaluation and significance of cytomegalovirus-specific cellular immune response in lung transplant recipients.
Costa C; Astegiano S; Terlizzi ME; Sidoti F; Curtoni A; Solidoro P; Baldi S; Bergallo M; Cavallo R
Transplant Proc; 2011 May; 43(4):1159-61. PubMed ID: 21620077
[TBL] [Abstract][Full Text] [Related]
10. CMV-Specific T Cell Monitoring Offers Superior Risk Stratification of CMV-Seronegative Kidney Transplant Recipients of a CMV-Seropositive Donor.
Schachtner T; Stein M; Reinke P
Transplantation; 2017 Oct; 101(10):e315-e325. PubMed ID: 28594749
[TBL] [Abstract][Full Text] [Related]
11. Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy.
Martín-Gandul C; Pérez-Romero P; Blanco-Lobo P; Benmarzouk-Hidalgo OJ; Sánchez M; Gentil MA; Bernal C; Sobrino JM; Rodríguez-Hernández MJ; Cordero E;
Transpl Int; 2014 Oct; 27(10):1060-8. PubMed ID: 24964364
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.
Abate D; Cesaro S; Cofano S; Fiscon M; Saldan A; Varotto S; Mengoli C; Pillon M; Calore E; Biasolo MA; Cusinato R; Barzon L; Messina C; Carli M; Palù G
Transplantation; 2012 Mar; 93(5):536-42. PubMed ID: 22314338
[TBL] [Abstract][Full Text] [Related]
13. T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients.
Gliga S; Korth J; Krawczyk A; Wilde B; Horn PA; Witzke O; Lindemann M; Fiedler M
J Clin Virol; 2018 Aug; 105():91-96. PubMed ID: 29936407
[TBL] [Abstract][Full Text] [Related]
14. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients.
Abate D; Saldan A; Mengoli C; Fiscon M; Silvestre C; Fallico L; Peracchi M; Furian L; Cusinato R; Bonfante L; Rossi B; Marchini F; Sgarabotto D; Rigotti P; Palù G
J Clin Microbiol; 2013 Aug; 51(8):2501-7. PubMed ID: 23678073
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the T-SPOT.CMV interferon-γ release assay in renal transplant recipients: A single center cohort study.
Chanouzas D; Small A; Borrows R; Ball S
PLoS One; 2018; 13(3):e0193968. PubMed ID: 29558479
[TBL] [Abstract][Full Text] [Related]
17. Human cytomegalovirus-specific T-cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infection.
Abate D; Fiscon M; Saldan A; Cofano S; Mengoli C; Sgarabotto D; d'Agostino C; Barzon L; Cusinato R; Toscano G; Feltrin G; Gambino A; Gerosa G; Palù G
J Clin Microbiol; 2012 Jun; 50(6):1974-80. PubMed ID: 22461674
[TBL] [Abstract][Full Text] [Related]
18. Early cytomegalovirus-specific T-cell response and estimated glomerular filtration rate identify patients at high risk of infection after renal transplantation.
Leone F; Gigliotti P; Mauro MV; Lofaro D; Greco F; Tenuta R; Perugini D; Papalia T; Mollica A; Perri A; Vizza D; La Russa A; Toteda G; Lupinacci S; Giraldi C; Bonofiglio R
Transpl Infect Dis; 2016 Apr; 18(2):191-201. PubMed ID: 26878346
[TBL] [Abstract][Full Text] [Related]
19. Cellular and humoral cytomegalovirus immunity changes in one-year combined prophylaxis after lung transplantation: suggestions from and for clinical practice.
Solidoro P; Patrucco F; Boffini M; Rinaldi M; Airoldi C; Costa C; Cavallo R; Albera C
Ther Adv Respir Dis; 2020; 14():1753466620981851. PubMed ID: 33356914
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.
Selvey LA; Lim WH; Boan P; Swaminathan R; Slimings C; Harrison AE; Chakera A
BMC Infect Dis; 2017 Jul; 17(1):501. PubMed ID: 28716027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]